It can be difficult to biopsy tissue from pancreatic neuroendocrine tumors (PNETs) for genomic profiling. To help create safe and non-invasive tests for genomic mutations before, during, and after treatment in PNET patients, NETRF is funding researchers that are testing a novel alternative known as a “liquid biopsy.”
Sharon Gorski, PhD, Genome Sciences Centre, Canada, has recently been awarded a two-year Neuroendocrine Tumor Research Foundation (NETRF)–American Association for Cancer Research (AACR) grant to use a new method of proteogenomic analysis on pancreatic neuroendocrine tumors (PNETs).
Laura Banaszynski, Ph.D., University of Texas Southwestern Medical Center – Laura Banaszynski, PhD, has always been passionate about science. After training as a chemical biologist, her innate curiosity pushed her to explore the mysteries of cells as a basic researcher.
Growing small intestinal organoids in a petri dish. Sequencing the “runaway” DNA of a pancreatic neuroendocrine tumor from a blood sample. Evaluating whether environmental or infectious agents contribute to the development of NETs. The research programs funded by NETRF this year push the search for the causes of this disease to the horizon of emerging scientific research.
(April 25, 2017, Boston, MA)—The Neuroendocrine Tumor Research Foundation (NETRF) today announced its largest research commitment ever—$4 million in collaborative grants—most from its new Accelerator
NETRF’s strong financial position, transparency, and accountability again earned it a 4-star rating by Charity Navigator, a national evaluator of nonprofits. The 4-star rating indicates
January 2016 eUpdate
CAR T (Chimeric Antigen Receptor T-cell) therapy, an immunotherapy that harnesses the body’s own T cells to kill cancer cells, showed success in treating blood
